VIVIPHARMA S.P.A. – Trademark Portfolio

Entity Type: 03

VIVIPHARMA S.P.A. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include REPHASE and CHRISSIE COSMETICS. The owner is based in Galazzano.

Via Guardia del Consiglio, 15

Galazzano 47891 , SM

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

VIVIPHARMA S.P.A.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

3
Cosmetics & Cleaning (4 filings)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does VIVIPHARMA S.P.A. have?

VIVIPHARMA S.P.A. has 5 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 2 cancelled.

What trademark classes does VIVIPHARMA S.P.A. file in?

VIVIPHARMA S.P.A. files trademarks across 2 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.

What are VIVIPHARMA S.P.A.'s most well-known trademarks?

VIVIPHARMA S.P.A.'s registered trademark portfolio includes well-known marks such as REPHASE and CHRISSIE COSMETICS. These are among 2 currently registered trademarks in the portfolio.

What is VIVIPHARMA S.P.A.'s trademark registration success rate?

VIVIPHARMA S.P.A. has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.